



Liquid Biopsy in Diseases

Guest Editors:

Prof. Dr. Sehyun Shin

1. School of Mechanical Engineering, College of Engineering, Korea University, 145 Anam-ro, Anam-dong, Seongbuk-gu, Seoul 136-701, Korea

2. Nano-Biofluignostic Engineering Research Center, Korea University, 145 Anam-ro, Anam-dong, Seongbuk-gu, Seoul 136-701, Korea

Dr. Kyong-Hwa Park

Division of Oncology/Hematology, Department of Internal Medicine, Korea University, Seoul 02841, Republic of Korea

Deadline for manuscript submissions:
closed (31 October 2022)

Message from the Guest Editors

In the age of precision medicine, tumor nucleic acid characterization plays an important role in providing patients with the most appropriate diagnosis and treatment. The advancements in PCR and next-generation sequencing (NGS) paved the way for personalized medicine by enabling the genetic characteristics of tumors to be evaluated. The development of blood-based liquid biopsy technology is also at the center of the development of precision medicine. In particular, liquid biopsy has emerged as the gold standard for diagnosis and treatment following its FDA approval in 2016.

We are inviting innovative and original research papers focused on the development of various technologies for cancer diagnosis and monitoring using liquid biopsy, focusing on the experimental/laboratory and pre-clinical medicine aspects. The submission of review articles describing the latest technology on this topic are also encouraged.

Focusing on liquid biopsy, this Special Issue covers the use of circulating tumor DNA (ctDNA), circulating tumor cells (CTC), circulating tumor RNA (ctRNA), miRNA, and extracellular vesicles (EV).





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)